Introduction
Status Epilepticus (SE) is a common neurological emergency with an annual incidence that varies from 9.9 to 41 per 100.000 people [1] [2] [3] [4] [5] [6] [7] [8] . SE is characterized by significant short-term morbidity and mortality [9] . Case fatality ranges from 5% to 46% [2] [3] [4] [5] [6] [7] [8] 10, 11] .
In this context, the assessment of the individual patient's prognosis as early as possible appears to be crucial in SE management, either to avoid over-treatment and its potentially harmful consequences [12] or to avoid under-detection and underAbbreviations: AUROC, area under the receiving operating curve; CSE, complex status epilepticus; EMSE, Epidemiology based Mortality score in Status Epilepticus; ICU, Intensive Care Unit; NCSE, non convulsive status epilepticus; NPV, negative predictive value; PPV, positive predictive value; ROC, receiving operating curve; SE, status epilepticus; STESS, Status Epilepticus Severity Score.
treatment. Moreover, predicting refractoriness of SE would be important for the correct management of SE itself (e.g. using continuous EEG monitoring, or rapid referral to an Intensive Care Unit, ICU).
To assess the short-term prognosis of SE, especially mortality, two different scores have been developed: STESS (Status Epilepticus Severity Score) [13, 14] and EMSE (Epidemiology based Mortality score in Status Epilepticus) [15, 16] .
The STESS was the first score developed to assess in-hospital mortality after SE [13] . STESS is a simple and quickly assessable score based on four parameters: level of consciousness before treatment administration, worst seizure type, age and history of previous seizures [13, 14] . The original cut-off value was set at three points (STESS-3), which means that scores 3 predict a high risk of death after a SE episode. STESS showed a high negative predictive value (NPV) for survival (100% and 97%), while it had a low positive predictive value (PPV) for death (37.5% and 39%) [13, 14] . This implies that it identifies patients who will survive a SE episode while it fails, in the majority of cases, to identify patients who will die due to a SE episode. In a subsequent study, Sutter et al. [18] set the cut-off at 4 points (STESS-4) allowing an increase of the correct classification value of the scale from 48.5% of STESS-3 to 73.1% of STESS-4.
The EMSE was introduced in 2015 [15, 16] . This is the first score based on available epidemiological or real world data. It uses four parameters: etiology, age (stratified by decade), comorbidity (based on the comorbidities reported in the Charlson's Comorbidity Index, [19] ) and EEG, with four different patterns: lateralized periodic discharges, generalized periodic discharges, after status epilepticus ictal discharges, and spontaneous burst suppression. The score was designed in a retrospective explorative study and the best cut-off was found to be 64 points, i.e. values of 64 or higher predict a higher likelihood of death. In that population EMSE had a NPV of 100%, PPV of 68.8% and correctly classified 89.1% of inhospital death [15, 16] . This meant it appeared to be useful in predicting bad outcomes as well as good outcomes after an episode of SE.
The aim of the present study was to evaluate and compare the predictive power of STESS-3, STESS-4 and EMSE-64 scores to determine treatment response, 30-days mortality, and 30-days disability in a group of adult patients followed up prospectively.
Material and methods

Type of study
This is a prospective observational study. We collected all SE episodes in young adults and adults (14 years old) within a 2-years period from September 1st 2013 to August 31st 2015.
Patients were observed at the Ospedale Civile Sant'Agostino Estense of Modena (regional center for neurological diseases for Modena city and district, Italy). For each included patient STESS and EMSE scores were calculated at baseline.
Inclusion/exclusion criteria and adopted definitions
Status epilepticus was defined as a continuous seizure or two or more discrete seizures between which there is no complete recovery of consciousness that lasts 5min for convulsive SE (CSE) [20, 21] . In cases of non convulsive status epilepticus (NCSE), which means a SE episode not accompanied by prominent motor phenomena or with subtle motor phenomena, a 30-min cut-off time was adopted. The most recent proposal for classification of SE used 10 min for NCSE [20] , but at the time the data were collected prospectively, 30 min cut-off was adopted.
Patients presenting two or more SE episodes during the study period were considered only for the first episode.
Enrollment strategy
We created a specific "Status Epilepticus Form" as a data gathering form to capture the information needed for each case. The form was filled in by the first treating physician who took care of the patient (in the majority of cases a neurologist, a neurointensivist, or an Accident and Emergency physician) or by the staff of the neurophysiology unit who performed the first EEG examination of a suspected SE case. In our centre a neurologist is on duty 24 h/day for seven days/week. The same neurophysiology staff recorded all EEGs and an epileptologist reviewed and updated all the forms and EEGs. Any missing information was completed using the hospital Informatics Database. As an additional quality control of the study protocol, we also checked all the patients discharged from the hospital in the two-year period being analysed with an "epilepsy" or "seizure" ICD-9 discharge code at the end of the study.
Outcome assessment
The outcomes were (a) response to treatment dichotomized in responsive or refractory SE on admission; (b) mortality and (c) level of disability at 30 days from SE onset.
Refractory Status Epilepticus (RSE) was defined as a SE episode that continues, regardless of the delay since the onset of the seizure, after failure of a trial of at least intravenous benzodiazepines and at least one AED, appropriately chosen and at adequate dosage. Thus, it required admission to the Intensive Care Unit (ICU) and the application of anesthetic drug therapy. Finally, Super-RSE (SRSE) was defined as SE that continues or recurs at least 24 h from the beginning of anesthetic therapy or recurs during the reduction or withdrawal of anesthesia [22] .
Functional outcome was assessed for each patient by calculating the modified Rankin Scale (mRS). According to the scale parameters, no disability or slight disability corresponded to a mRS 2; moderate disability was considered mRS 3-4 and severe disability mRS 5; mRS 6 was death. For each patient, the value of mRS at the 30-days follow-up was compared to the level of disability before the hospital admission (pre-mRS).
Statistical analysis
Descriptive statistics were used to analyse clinical and demographical variables in the whole population.
Diagnostic accuracy for STESS and EMSE-64 in classifying patients according to each outcome was assessed by creating Receiver Operating Characteristic (ROC) curves with different cutoff levels and calculating the AUROC (Area under ROC). Sensitivity, specificity, PPV and NPV were calculated for each scale. McNemar test was used to compare sensitivity and specificity between STESS (with different cutoff values) and EMSE-64.
The equivalency of the AUROCs was compared using an algorithm suggested by De Long et al. [23] in order to establish the best performance test for each outcome. All statistical analyses were performed using Stata11 Software.
Results
Patient population
During the two-year study we observed 175 SE episodes occurring in 162 patients. Eight patients had two or more SE episodes during the years of observation, thus the recurrence rate was 4.6%. The 162 first episodes of SE received further analysis. Table 1 provides the demographic, clinical data and EEG features of the patients.
The detailed distribution of the STESS and EMSE parameters in our population is reported in Table 2 and Table 3 respectively. The mean STESS score was 3 points. This value was observed in 57 patients (35%). Considering the cut-off of 3 points 112 patients (69%) had a STESS score 3, while increasing the cut-off at 4 points 55 patients (34%) had a STESS score 4. Considering the EMSE score with a cut-off value of 64 points, 82 patients (51%) presented an EMSE 64 points, while 80 patients (49%) showed an EMSE <64 points.
STESS and EMSE in mortality prediction
We observed a 30-days mortality of 31.5% (51 deceased patients). Sensitivity, specificity, PPV and NPV of each scale are showed in Fig. 1a .
Considering the 30-days mortality prediction, STESS-3 had a high sensitivity (86.3%) and a low specificity (38.7%). Applying STESS-4 the specificity increased (73%) while the sensitivity decreased (49%).
A direct comparison of sensitivity between STESS and EMSE showed that EMSE-64 had higher sensitivity compared to STESS-4 (p < 0.001) but not compared to STESS-3 (p = 0.12). A direct comparison of specificity between STESS and EMSE showed that EMSE-64 had higher specificity compared to STESS-3 (p < 0.001) but not compared to STESS-4 (p = 0.76).
Notably, EMSE-64 showed a high negative predictive value (NPV, 97.5%) and positive predictive value (PPV, 59.8%).
The equality test of AUROCS showed that EMSE-64 appeared to be superior to STESS (considering both cutoff values of 3 and 4). Thus EMSE-64 has the highest accuracy (0.83) in predicting 30-days mortality after a SE episode, which was significantly superior to STESS-scores (Fig. 1b) .
STESS and EMSE in prediction of clinical worsening
At baseline 103 patients (63.6%) had no disabilities or a slight disability (mRS 0-2). At 30 days post-SE only 55 patients (34%) had a mRS 0-2. Comparing the 30 days follow-up mRS values to the baseline values, we found that 95 patients (59%) had worsened functional conditions. Sensitivity, specificity, PPV and NPV of the three scales are showed in Fig. 2a .
Again we found that STESS-3 had a high sensitivity (80%) and a low specificity (46.3%) while adopting STESS-4 the specificity increased to 79.1% while the sensitivity decreased to 43.2%.
EMSE-64 showed higher sensitivity compared to STESS-4 (p < 0.001) but not compared to STESS-3 (p = 0.57); specificity was higher for EMSE-64 in comparison to STESS-3 (p < 0.001) but not compared to STESS-4 (p = 0.76). EMSE-64 showed the highest PPV (87.8%), and NPV (71.3%).
The comparison of the accuracy of prediction of clinical worsening among the three scores showed that EMSE-64 had a significantly higher accuracy when compared both to STESS-4 (p < 0.0001) and STESS-3 (p = 0.0001). The direct comparison of the accuracy of STESS-3 and STESS-4 did not show significant differences between them. The comparison of AUROC of the three scales is showed in Fig. 2b. 
STESS and EMSE in refractoriness prediction
108 patients (66.7%) had a SE responsive to first or second line treatment, while 37 patients (22.8%) had a refractory SE, thus needed admission to ICU and anesthetic therapy. Among them, 26 (16%) were defined as super-refractory. For 17 patients (10.5%) it was not possible to define the treatment response, as though they did not respond to the second line treatment, there was no therapy escalation due to an "end-of-life approach" and all of them died whilst still in SE.
All three scales had a high NPV (87.3% for the EMSE-64, 87.5% for the STESS-3 and 89.4% for the STESS-4) for prediction of refractoriness to treatment. Conversely they all showed a low PPV (40.9% for the EMSE, 32% for the STESS-3 and 52.9% for the STESS-4). The sensitivity was high for all three scales (without statistically significant differences), while the highest specificity was showed by STESS-4 (STESS-4 vs STESS 3, p = 0.000; STESS-4 versus EMSE-64, p = 0.006).
The sensitivity, specificity, PPV, NPV of the three scales are shown in Fig. 3a .
The comparison of the accuracy of the three scales in predicting refractoriness showed that STESS-4 had the highest accuracy. The direct comparison of the accuracy of STESS-4 and STESS-3 shows that STESS-4 was superior to STESS-3 (p = 0.0001). When STESS-4 and STESS-3 were compared to EMSE-64 their accuracies were not significantly different. The comparison of AUROC of the three scales is shown in Fig. 3b . a Unclassified: Patients for which it was not possible to define the treatment response, as even if they did not respond to the second line treatment, there was no therapy escalation due to an "end-of-life approach" and all of them died being still in SE (see text).
Discussion
In the present study we found that EMSE was superior to STESS in predicting both short-term mortality and morbidity after SE, while both scores are less useful in predicting refractoriness to treatment. In particular, an EMSE <64 points suggests to the clinician that the patient has a high probability of surviving (98%) without functional decline after the SE episode. Thus, this gives the possibility to avoid an unnecessary overtreatment and its related possible complications. In contrast an EMSE 64 points informs the clinician that the patient has a high probability (88%) of worsening and death (60%) after the SE episode indicating that it is of paramount importance to rapidly and intensively manage the patient (SE treatment, EEG monitoring, etiology identification and treatment, complications avoidance) to avoid a possible negative outcome.
As far as mortality prediction EMSE-64 showed a high sensitivity (96%) but a relatively low specificity (70%) reflecting the low proportion of false negative (2.5%) and the relatively high proportion of false positive (40%) cases. These patients mainly had a SE episode related to acute strokes, anoxic brain injury or brain tumors: all etiologies known to be related to high mortality. Indeed, considering the mortality at 6 months from SE onset 30% of these patients were dead. Notably, since the EMSE uses four nonmodifiable parameters to assess mortality prediction it is nevertheless possible that medical interventions (e.g. rapid SE drug treatment, rapid identification and whenever possible treatment of the underlying conditions, management and prevention of complications) could improve the outcome.
Overall, these findings confirm previous results of the study of Leitinger et al. [15, 16] , highlighting the good accuracy of EMSE-64 in predicting short-term mortality after a SE episode and its superiority to STESS. In contrast, Kang et al. [24] showed no differences between STESS and EMSE in mortality prediction, but in that study the authors did not use the EMSE-64 score as originally proposed (different cut-off values and different parameters), and therefore it is not possible to compare results. In Supplementary Table S1, in the online version at DOI: 10.1016/j. seizure.2017.01.004, the results of the published studies of mortality prediction with the STESS and EMSE-64 scores are summarized [13] [14] [15] 18, 24, 25] .
With regards to the prediction of clinical worsening, EMSE-64 again showed a significantly higher accuracy when compared to both STESS-3 and to STESS-4 with a sensitivity of nearly 76% and specificity of 85%. EMSE >64 points means an 88% probability of worsening the clinical condition at 30-days follow-up, while an EMSE score <64 points means a 71% probability of regaining the previous clinical status before the SE episode. Since the patient has a 29% risk of worsening as well, this means that even if the test is negative the patient has a significant possibility of experiencing an adverse outcome. This has to be kept in mind in the treatment/ management of the SE episode. In this case only ten patients were false positives.
To the best of our knowledge, only two studies compared STESS and EMSE scores in predicting functional outcome at hospital [17, 24] concluded that the EMSE had a higher accuracy in predicting functional outcome when compared to STESS at hospital discharge and at 3 months post-discharge. They also found that the END-IT (Encephalitis, Non-convulsive status epilepticus, Diazepam resistance, Image abnormality, Tracheal intubation) score was significantly superior to STESS (with both cut-off levels 3 and 4) and without statistically significant differences with the EMSE. With regards to the END-IT, however, the score was developed to assess the 3 months prognosis in a convulsive SE population, therefore we believed it was not suitable for use to determine 30 days morbidity in our population (with 115 NCSE cases, 71% of our population). Finally, relating to refractoriness prediction, the three scales all showed a high NPV thus a patient with a negative score has a high probability of treatment responsiveness. On the other hand, they all had a low PPV (40.9% for the EMSE, 32% for the STESS-3 and 52.9% for the STESS-4) thus in a patient with positive score it is not possible to predict the response to treatment. The low accuracy of the three scales in SE refractoriness prediction implies that their clinical usefulness is limited.
Whilst STESS was created to assess in-hospital mortality, it has since been used to predict refractoriness to treatment [26, 27] . In the study of Novy et al. [26] , STESS 3 was found to be strongly associated with the presence of RSE (p = 0.001) but it was not used to predict refractoriness. In the study of Sutter et al. [27] , the only study, to the best of our knowledge, that evaluated STESS-3 to predict SE refractoriness, the authors concluded that STESS failed to reliably predict refractoriness (AUROC 0.58 in the Swiss population and 0.60 in the US population respectively). 
Study limitations
Even if our population was prospectively and consecutively collected, this study represents a 'one center' experience. This could represent a potential bias since the accuracy of the evaluated scores could be different in relation to the severity of the examined population. However, our hospital is a regional care clinic that seems to be representative of non-selected status epilepticus patients. In the analyzed population, only 14 patients had a SE episode relating to a precipitating factor in a previous epilepsy history: an etiology well known to have a good prognosis and corresponding low scores on STESS and EMSE. Our population showed a distribution of scores that appeared to be similar to the ones previously reported in the Austrian population (68.5% of patients had a STESS 3) [15] but higher than the ones observed in the Swiss population (51.9% of patients had a STESS 3) [14] and in the study of Goyal et al. [25] in whom only 27.3% of patients had a STESS 3. Therefore, larger multicenter prospective studies are strongly advised to evaluate the accuracy of these scales.
Conclusions
This study highlights the superiority of EMSE on STESS in mortality and clinical worsening predictions after an episode of SE, thus EMSE could be adopted in everyday clinical practice as a quick bedside evaluation. However, we confirm that, at present, there are no reliable scores to predict treatment refractoriness. Given that, we think that it would be useful to create a more dynamic score, that consider modifiable variables (as, for example, development of in-hospital complications) to be calculated daily in SE patients, as it is for NIHSS (National Institutes of Health Stroke Scale) [28] in stroke patients, thus giving the clinician a more precise idea of the clinical evolution and, perhaps, refractoriness development.
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